Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.

Eva Maria GamperJammbe Z MusoroCorneel CoensJean-Jacques StelmesClaudette FalatoMogens GroenvoldGalina VelikovaKim CocksHans-Henning FlechtnerMadeleine T KingAndrew Bottomleynull null

Published in: BMC cancer (2021)

Our findings aid the meaningful interpretation of changes on a set of EORTC QLQ-C30 scale scores over time, both within and between groups, and for performing more accurate sample size calculations for clinical trials in prostate cancer.

Keyphrases

prostate cancer
clinical trial
radical prostatectomy
phase ii
density functional theory
molecular dynamics
high resolution
molecular dynamics simulations
study protocol
phase iii